Incyte Corp.
Incyte Corp. is classed by the SEC under Services-Commercial Physical & Biological Research (industry code 8731), based in Wilmington, DE. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $5.1 billion and a profit of $1.3 billion (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a project business: prior from its industry code (SEC 8731, Services-Commercial Physical & Biological Research); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 7.7 out of ten, 9 of 9 metrics filed: past 7.5 out of ten, present 7.7 out of ten, future 7.8 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 7.9 out of ten. No warning events in its filings since 2017. 79th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 7.5 out of ten. +16.3% a year over 9 filed years; profitable in 7 of 9. 75th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 6.9 out of ten. Share count shrank 3.6% a year. 89% of cash flow returned. Insiders: 47 sales, 0 purchases. 69th percentile among 6 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 7.5 out of ten. ROE 25%: 25¢ of profit per shareholder dollar. Leverage 26%: owes 26¢ per asset dollar. 75th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 8.5 out of ten. top 15% of 12 in its family; net margin 25%. 85th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 6.7 out of ten. top 33% of 8 in its family for leadership; chief executive since 2025. 67th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 7.2 out of ten. top 28% of 12 in its family for room to expand. 72nd percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 7.7 out of ten. top 23% of 12 in its family for growth drivers. 77th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 8.6 out of ten. top 14% of 11 in its family for expectations against reality. 86th percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-10 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-28 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-28 (on EDGAR). Newest filing: Form 4, 2026-10-05. Filings on record since 1994. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: JAKAFI 60%, OPZELURA 13%, JAKAVI Royalty Revenues 9%, NIKTIMVO 3%, Milestone and Contract Revenues 3%, Olumiant Royalty 3%. By geography: United States 93%, Europe 6%, Other countries under 1%. As tagged in its annual report (Form 10-K, filed 2026-02-10).
Who runs it
Meury, William (Chief Executive Officer); Hoppenot, Herve (Special Advisor to the CEO); Cagnoni, Pablo J (President, Global Head of R&D); Upadhyay, Suketu (EVP & Chief Financial Officer); Stamoulis, Christiana (EVP & Chief Financial Officer); Gardner, David H (EVP, Chief Strategy Officer); Mayes, Patrick A (EVP & Chief Scientific Officer); Heeson, Lee (EVP, Head of Incyte Intl); Basi, Ramitpal K (EVP, Human Resources); Morrissey, Michael James (EVP, Head of Tech. Operations); and 21 more. 31 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-05.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.